Every denied dermatology claim is revenue your practice already earned. AAPC-certified coders turn Mohs stages, biologics authorizations, and modifier 25 into paid claims, not appeals.
Schedule a consultation
Dermatology claims fail in specific, predictable spots: A biopsy coded by habit instead of technique, a biologic prior authorization missing a severity score, a telederm visit billed on last year’s place-of-service code. Dermatology billing services built for family practice or general surgery miss these details, because dermatology runs on lesion counts, Mohs stages, and a cosmetic-versus-medical line payers scrutinize harder every year.
HelloMDs is backed by 15+ years of revenue cycle experience, a 99% first-pass ratio, and AAPC-certified coders; we support dermatology practices nationwide.
Four shifts are behind most of this year’s claim rejections.
AI-driven claim screening - National payers now run algorithmic review before a person opens the file, and dermatology's cosmetic-and-medical mix gets flagged more than most specialties.
Biologic prior authorization - Psoriasis, atopic dermatitis, and hidradenitis biologics need step-therapy and severity documentation that payers are rejecting more often than last year.
Telederm place-of-service confusion - Medicare, Medicaid, and commercial plans disagree on which POS code and modifier apply to the same virtual visit.
Lesion-level documentation - A biopsy, destruction, or excision claim lives or dies on the exact count, size, and site written in the chart note.
Coders who work skin claims daily know a Mohs stage from a destruction code without looking it up twice.
Every claim runs through a certified coder, not an entry-level queue learning dermatology from scratch.
A 99% first-pass ratio and a 15% average drop in denial rates, company-wide.
The same people stay on your account, so payer rules and past denials don't get relearned every quarter.
Real-time claim status and AR aging, not a spreadsheet that shows up once a month.
Tangential (11102/11103), punch (11104/11105), and incisional (11106/11107) biopsies get coded by technique, and actinic keratosis destruction (L57.0) gets billed correctly across 17000, 17003, and 17004 by lesion count.
Stage-by-stage coding across 17311-17315, lesion by lesion, with modifier 59 attached where a payer requires it, so a multi-lesion Mohs day isn’t flattened into one underpaid line.
Step-therapy history and severity scores get filed at the point of prescribing, with a follow-up trigger before the authorization window closes.
Place-of-service and modifier pairing gets checked against each payer’s current rule before the visit, not after the denial.
Every rejected dermatology claim gets worked and refiled, and modifier 25/59 documentation checked before resubmission.
01
Step-therapy and severity notes get tracked before the script goes out, not after a pharmacy call.
02
Clean claims move through payers without sitting in a rework queue.
03
Active follow-up starts at 30 days past due, not 90.
04
Coding and authorization work moves off staff who are already booking patients.
05
Denial trends and AR aging show up in reporting as they happen.
| Where It Breaks | How HelloMDs Fixes It |
|---|---|
| Cosmetic vs. medical coding | Every borderline procedure gets a documented medical indication before the claim goes out. |
| Biologic PA denials | Step-therapy and severity documentation get tracked from the prescribing date, with a five-day follow-up trigger. |
| Modifier 25/59 misuse | Same-day E/M plus biopsy or excision gets backed by a distinct exam note before submission. |
| Telederm POS mismatches | Each payer's current place-of-service and modifier rule gets confirmed before the visit is billed. |
| Lesion documentation gaps | Exact count, size, and site get recorded for every biopsy, destruction, and excision claim. |
| Credentialing delays | Provider enrollment and revalidation get tracked across every payer on the panel. |
The feedback and experiences shared by our clients inspire us to continually improve, innovate, and deliver smarter solutions. Here’s what healthcare professionals are saying about their experience with Hello MDs and why you can trust on us by knowing their experiences.
A free review of your last 90 days of claims highlights denied procedures, modifier issues, unpaid biologic authorizations, aging accounts receivable, and payer trends that keep revenue from reaching your practice.
Biopsy codes (11102-11107 by technique), lesion-destruction codes (17000/17003/17004 for actinic keratosis), and Mohs codes (17311-17315) cover a large share of dermatology claims, alongside standard E/M codes 99202-99215.
Payers want fuller step-therapy history and validated severity scores (PASI or EASI) before approving a biologic, and algorithmic claim review flags incomplete files earlier than a manual reviewer would.
The E/M code usually stays the same (99202-99215); Medicare wants POS 11 with modifier 95, while commercial plans often want POS 10 or 02 instead.
Only when the chart supports a medical indication. A payer that finds a cosmetic procedure billed as medically necessary without that documentation denies the claim and may flag the practice on future submissions.
Plans start as low as 2.95% of monthly collections, priced to practice size and claim volume. A free billing review shows the current denial pattern and where the percentage lands.
A dermatology billing company codes visits, biopsies, excisions, and Mohs stages, then submits, tracks, and appeals claims for the practice. HelloMDs also runs eligibility checks, biologics prior authorization, and payer credentialing for dermatology groups nationwide.
Mohs surgery bills CPT 17311 or 17313 for the first stage, depending on anatomic site, then 17312 or 17314 for each additional stage, and 17315 for blocks past five within one stage. The operative note has to document the exact block count per stage.
Yes. HelloMDs bills for dermatopathology services by assigning accurate CPT and ICD-10 codes, submitting pathology claims, verifying documentation, managing payer requirements, and following up on denied or unpaid claims to keep reimbursements on track.
